Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47


Expression and crystallographic studies of the D1D2 domains of C4.4A, a homologous protein to the urokinase receptor.

Chen S, Lin L, Yuan C, Gårdsvoll H, Kriegbaum MC, Ploug M, Huang M.

Acta Crystallogr F Struct Biol Commun. 2017 Aug 1;73(Pt 8):486-490. doi: 10.1107/S2053230X17009748. Epub 2017 Jul 27.


The collagen receptor uPARAP/Endo180 as a novel target for antibody-drug conjugate mediated treatment of mesenchymal and leukemic cancers.

Nielsen CF, van Putten SM, Lund IK, Melander MC, Nørregaard KS, Jürgensen HJ, Reckzeh K, Christensen KR, Ingvarsen SZ, Gårdsvoll H, Jensen KE, Hamerlik P, Engelholm LH, Behrendt N.

Oncotarget. 2017 Jul 4;8(27):44605-44624. doi: 10.18632/oncotarget.17883.


The acidic domain of the endothelial membrane protein GPIHBP1 stabilizes lipoprotein lipase activity by preventing unfolding of its catalytic domain.

Mysling S, Kristensen KK, Larsson M, Beigneux AP, Gårdsvoll H, Fong LG, Bensadouen A, Jørgensen TJ, Young SG, Ploug M.

Elife. 2016 Jan 3;5:e12095. doi: 10.7554/eLife.12095.


Mapping the topographic epitope landscape on the urokinase plasminogen activator receptor (uPAR) by surface plasmon resonance and X-ray crystallography.

Zhao B, Gandhi S, Yuan C, Luo Z, Li R, Gårdsvoll H, de Lorenzi V, Sidenius N, Huang M, Ploug M.

Data Brief. 2015 Sep 4;5:107-13. doi: 10.1016/j.dib.2015.08.027. eCollection 2015 Dec.


Urokinase receptor cleavage correlates with tumor volume in a transgenic mouse model of breast cancer.

Thurison T, Almholt K, Gårdsvoll H, Ploug M, Høyer-Hansen G, Lund IK.

Mol Carcinog. 2016 May;55(5):717-31. doi: 10.1002/mc.22316. Epub 2015 Mar 25.


Stabilizing a flexible interdomain hinge region harboring the SMB binding site drives uPAR into its closed conformation.

Zhao B, Gandhi S, Yuan C, Luo Z, Li R, Gårdsvoll H, de Lorenzi V, Sidenius N, Huang M, Ploug M.

J Mol Biol. 2015 Mar 27;427(6 Pt B):1389-1403. doi: 10.1016/j.jmb.2015.01.022. Epub 2015 Feb 7.


GPIHBP1 missense mutations often cause multimerization of GPIHBP1 and thereby prevent lipoprotein lipase binding.

Beigneux AP, Fong LG, Bensadoun A, Davies BS, Oberer M, Gårdsvoll H, Ploug M, Young SG.

Circ Res. 2015 Feb 13;116(4):624-32. doi: 10.1161/CIRCRESAHA.116.305085. Epub 2014 Nov 11.


Multimerization of glycosylphosphatidylinositol-anchored high density lipoprotein-binding protein 1 (GPIHBP1) and familial chylomicronemia from a serine-to-cysteine substitution in GPIHBP1 Ly6 domain.

Plengpanich W, Young SG, Khovidhunkit W, Bensadoun A, Karnman H, Ploug M, Gårdsvoll H, Leung CS, Adeyo O, Larsson M, Muanpetch S, Charoen S, Fong LG, Niramitmahapanya S, Beigneux AP.

J Biol Chem. 2014 Jul 11;289(28):19491-9. doi: 10.1074/jbc.M114.558528. Epub 2014 May 20.


The urokinase receptor homolog Haldisin is a novel differentiation marker of stratum granulosum in squamous epithelia.

Gårdsvoll H, Kriegbaum MC, Hertz EP, Alpízar-Alpízar W, Ploug M.

J Histochem Cytochem. 2013 Nov;61(11):802-13. doi: 10.1369/0022155413501879. Epub 2013 Jul 29.


Targeting a single function of the multifunctional matrix metalloprotease MT1-MMP: impact on lymphangiogenesis.

Ingvarsen S, Porse A, Erpicum C, Maertens L, Jürgensen HJ, Madsen DH, Melander MC, Gårdsvoll H, Høyer-Hansen G, Noel A, Holmbeck K, Engelholm LH, Behrendt N.

J Biol Chem. 2013 Apr 12;288(15):10195-204. doi: 10.1074/jbc.M112.447169. Epub 2013 Feb 14.


Targeting tumor cell invasion and dissemination in vivo by an aptamer that inhibits urokinase-type plasminogen activator through a novel multifunctional mechanism.

Botkjaer KA, Deryugina EI, Dupont DM, Gårdsvoll H, Bekes EM, Thuesen CK, Chen Z, Ploug M, Quigley JP, Andreasen PA.

Mol Cancer Res. 2012 Dec;10(12):1532-43. doi: 10.1158/1541-7786.MCR-12-0349. Epub 2012 Oct 4. Erratum in: Mol Cancer Res. 2013 Aug;11(8):964. Chen, Zhou [corrected to Chen, Zhuo].


A flexible multidomain structure drives the function of the urokinase-type plasminogen activator receptor (uPAR).

Mertens HD, Kjaergaard M, Mysling S, Gårdsvoll H, Jørgensen TJ, Svergun DI, Ploug M.

J Biol Chem. 2012 Oct 5;287(41):34304-15. doi: 10.1074/jbc.M112.398404. Epub 2012 Aug 15.


Crystal structure of the urokinase receptor in a ligand-free form.

Xu X, Gårdsvoll H, Yuan C, Lin L, Ploug M, Huang M.

J Mol Biol. 2012 Mar 9;416(5):629-41. doi: 10.1016/j.jmb.2011.12.058. Epub 2012 Jan 21. Erratum in: J Mol Biol. 2012 Sep 7;422(1):158.


Mimicry of the regulatory role of urokinase in lamellipodia formation by introduction of a non-native interdomain disulfide bond in its receptor.

Gårdsvoll H, Kjaergaard M, Jacobsen B, Kriegbaum MC, Huang M, Ploug M.

J Biol Chem. 2011 Dec 16;286(50):43515-26. doi: 10.1074/jbc.M111.300020. Epub 2011 Oct 24.


Plasmodium ookinetes coopt mammalian plasminogen to invade the mosquito midgut.

Ghosh AK, Coppens I, Gårdsvoll H, Ploug M, Jacobs-Lorena M.

Proc Natl Acad Sci U S A. 2011 Oct 11;108(41):17153-8. doi: 10.1073/pnas.1103657108. Epub 2011 Sep 26.


Conformational regulation of urokinase receptor function: impact of receptor occupancy and epitope-mapped monoclonal antibodies on lamellipodia induction.

Gårdsvoll H, Jacobsen B, Kriegbaum MC, Behrendt N, Engelholm L, Østergaard S, Ploug M.

J Biol Chem. 2011 Sep 23;286(38):33544-56. doi: 10.1074/jbc.M111.220087. Epub 2011 Jul 28.


A novel functional role of collagen glycosylation: interaction with the endocytic collagen receptor uparap/ENDO180.

Jürgensen HJ, Madsen DH, Ingvarsen S, Melander MC, Gårdsvoll H, Patthy L, Engelholm LH, Behrendt N.

J Biol Chem. 2011 Sep 16;286(37):32736-48. doi: 10.1074/jbc.M111.266692. Epub 2011 Jul 18.


Rational targeting of the urokinase receptor (uPAR): development of antagonists and non-invasive imaging probes.

Kriegbaum MC, Persson M, Haldager L, Alpízar-Alpízar W, Jacobsen B, Gårdsvoll H, Kjær A, Ploug M.

Curr Drug Targets. 2011 Nov;12(12):1711-28. Review.


Selective abrogation of the uPA-uPAR interaction in vivo reveals a novel role in suppression of fibrin-associated inflammation.

Connolly BM, Choi EY, Gårdsvoll H, Bey AL, Currie BM, Chavakis T, Liu S, Molinolo A, Ploug M, Leppla SH, Bugge TH.

Blood. 2010 Sep 2;116(9):1593-603. doi: 10.1182/blood-2010-03-276642. Epub 2010 May 13.


Purification and characterization of recombinant full-length and protease domain of murine MMP-9 expressed in Drosophila S2 cells.

Rasch MG, Lund IK, Illemann M, Høyer-Hansen G, Gårdsvoll H.

Protein Expr Purif. 2010 Jul;72(1):87-94. doi: 10.1016/j.pep.2010.03.002. Epub 2010 Mar 7.


Structure-based engineering of species selectivity in the interaction between urokinase and its receptor: implication for preclinical cancer therapy.

Lin L, Gårdsvoll H, Huai Q, Huang M, Ploug M.

J Biol Chem. 2010 Apr 2;285(14):10982-92. doi: 10.1074/jbc.M109.093492. Epub 2010 Feb 4.


Interactions of plasminogen activator inhibitor-1 with vitronectin involve an extensive binding surface and induce mutual conformational rearrangements.

Blouse GE, Dupont DM, Schar CR, Jensen JK, Minor KH, Anagli JY, Gårdsvoll H, Ploug M, Peterson CB, Andreasen PA.

Biochemistry. 2009 Mar 3;48(8):1723-35. doi: 10.1021/bi8017015.


Antibody-mediated targeting of the urokinase-type plasminogen activator proteolytic function neutralizes fibrinolysis in vivo.

Lund IK, Jögi A, Rønø B, Rasch MG, Lund LR, Almholt K, Gårdsvoll H, Behrendt N, Rømer J, Høyer-Hansen G.

J Biol Chem. 2008 Nov 21;283(47):32506-15. doi: 10.1074/jbc.M801924200. Epub 2008 Sep 17.


Structure and ligand interactions of the urokinase receptor (uPAR).

Kjaergaard M, Hansen LV, Jacobsen B, Gardsvoll H, Ploug M.

Front Biosci. 2008 May 1;13:5441-61.


A composite role of vitronectin and urokinase in the modulation of cell morphology upon expression of the urokinase receptor.

Hillig T, Engelholm LH, Ingvarsen S, Madsen DH, Gårdsvoll H, Larsen JK, Ploug M, Danø K, Kjøller L, Behrendt N.

J Biol Chem. 2008 May 30;283(22):15217-23. doi: 10.1074/jbc.C700214200. Epub 2008 Mar 24.


Solution structure of recombinant somatomedin B domain from vitronectin produced in Pichia pastoris.

Kjaergaard M, Gårdsvoll H, Hirschberg D, Nielbo S, Mayasundari A, Peterson CB, Jansson A, Jørgensen TJ, Poulsen FM, Ploug M.

Protein Sci. 2007 Sep;16(9):1934-45.


Extracellular collagenases and the endocytic receptor, urokinase plasminogen activator receptor-associated protein/Endo180, cooperate in fibroblast-mediated collagen degradation.

Madsen DH, Engelholm LH, Ingvarsen S, Hillig T, Wagenaar-Miller RA, Kjøller L, Gårdsvoll H, Høyer-Hansen G, Holmbeck K, Bugge TH, Behrendt N.

J Biol Chem. 2007 Sep 14;282(37):27037-45. Epub 2007 Jul 9.


Murine monoclonal antibodies against murine uPA receptor produced in gene-deficient mice: inhibitory effects on receptor-mediated uPA activity in vitro and in vivo.

Pass J, Jögi A, Lund IK, Rønø B, Rasch MG, Gårdsvoll H, Lund LR, Ploug M, Rømer J, Danø K, Høyer-Hansen G.

Thromb Haemost. 2007 Jun;97(6):1013-22.


A new tagging system for production of recombinant proteins in Drosophila S2 cells using the third domain of the urokinase receptor.

Gårdsvoll H, Hansen LV, Jørgensen TJ, Ploug M.

Protein Expr Purif. 2007 Apr;52(2):384-94. Epub 2006 Dec 2.


One-step affinity purification of recombinant urokinase-type plasminogen activator receptor using a synthetic peptide developed by combinatorial chemistry.

Jacobsen B, Gårdsvoll H, Juhl Funch G, Ostergaard S, Barkholt V, Ploug M.

Protein Expr Purif. 2007 Apr;52(2):286-96. Epub 2006 Aug 30.


Characterization of the functional epitope on the urokinase receptor. Complete alanine scanning mutagenesis supplemented by chemical cross-linking.

Gårdsvoll H, Gilquin B, Le Du MH, Ménèz A, Jørgensen TJ, Ploug M.

J Biol Chem. 2006 Jul 14;281(28):19260-72. Epub 2006 May 3.


A region in urokinase plasminogen receptor domain III controlling a functional association with alpha5beta1 integrin and tumor growth.

Chaurasia P, Aguirre-Ghiso JA, Liang OD, Gardsvoll H, Ploug M, Ossowski L.

J Biol Chem. 2006 May 26;281(21):14852-63. Epub 2006 Mar 17.


Collisional activation by MALDI tandem time-of-flight mass spectrometry induces intramolecular migration of amide hydrogens in protonated peptides.

Jørgensen TJ, Bache N, Roepstorff P, Gårdsvoll H, Ploug M.

Mol Cell Proteomics. 2005 Dec;4(12):1910-9. Epub 2005 Aug 27.


Crystal structure of the human urokinase plasminogen activator receptor bound to an antagonist peptide.

Llinas P, Le Du MH, Gårdsvoll H, Danø K, Ploug M, Gilquin B, Stura EA, Ménez A.

EMBO J. 2005 May 4;24(9):1655-63. Epub 2005 Apr 7.


Intramolecular migration of amide hydrogens in protonated peptides upon collisional activation.

Jørgensen TJ, Gårdsvoll H, Ploug M, Roepstorff P.

J Am Chem Soc. 2005 Mar 2;127(8):2785-93.


Dynamics of urokinase receptor interaction with Peptide antagonists studied by amide hydrogen exchange and mass spectrometry.

Jørgensen TJ, Gårdsvoll H, Danø K, Roepstorff P, Ploug M.

Biochemistry. 2004 Nov 30;43(47):15044-57.


Specific immunoassays for detection of intact and cleaved forms of the urokinase receptor.

Piironen T, Laursen B, Pass J, List K, Gårdsvoll H, Ploug M, Danø K, Høyer-Hansen G.

Clin Chem. 2004 Nov;50(11):2059-68. Epub 2004 Sep 2.


Structural analysis and tissue localization of human C4.4A: a protein homologue of the urokinase receptor.

Hansen LV, Gårdsvoll H, Nielsen BS, Lund LR, Danø K, Jensen ON, Ploug M.

Biochem J. 2004 Jun 15;380(Pt 3):845-57.


Structural analysis of the interaction between urokinase-type plasminogen activator and its receptor: a potential target for anti-invasive cancer therapy.

Ploug M, Gårdsvoll H, Jørgensen TJ, Lønborg Hansen L, Danø K.

Biochem Soc Trans. 2002 Apr;30(2):177-83. Review.


Peptide-derived antagonists of the urokinase receptor. affinity maturation by combinatorial chemistry, identification of functional epitopes, and inhibitory effect on cancer cell intravasation.

Ploug M, Østergaard S, Gårdsvoll H, Kovalski K, Holst-Hansen C, Holm A, Ossowski L, Danø K.

Biochemistry. 2001 Oct 9;40(40):12157-68.


Generation of high-affinity rabbit polyclonal antibodies to the murine urokinase receptor using DNA immunization.

Gårdsvoll H, Solberg H, Dano K, Høyer-Hansen G.

J Immunol Methods. 2000 Feb 3;234(1-2):107-16.


Selection of peptides that bind to plasminogen activator inhibitor 1 (PAI-1) using random peptide phage-display libraries.

Gårdsvoll H, van Zonneveld AJ, Holm A, Eldering E, van Meijer M, Danø K, Pannekoek H.

FEBS Lett. 1998 Jul 17;431(2):170-4.


Plasminogen activator inhibitor type 1 in cancer: therapeutic and prognostic implications.

Pappot H, Gårdsvoll H, Rømer J, Pedersen AN, Grøndahl-Hansen J, Pyke C, Brünner N.

Biol Chem Hoppe Seyler. 1995 May;376(5):259-67. Review.


Supplemental Content

Loading ...
Support Center